The latest survey from the National Venture Capital Association shows that biotechnology is still on a roll with investors. The association tracked 99 biotech deals in the third quarter which were worth $1.1 billion. Frazier Healthcare Ventures is so pumped about developers it's reserved half of its latest $600 million fund for biotech deals. An ongoing obstacle: A reluctance among VCs to back early-stage ventures. Most worrisome trend: The prospect that a new group of politicos in charge of healthcare legislation in Washington DC will chill the life sciences field with talk of reform.
- read the report from BioWorld on venture capital trends
Venture capitalists bet big on nanotechnology. Report
Bill could improve funding for small biotechs. Report
Biotech sees big money from corporate players. Report
The Top 5 VC deals of the first half of 2007. Report